Price cut? What price cut?
Turing Pharmaceuticals, the company that recently ignited a firestorm of controversy after it hiked the price of a drug by more than 5,000 percent overnight just released what it called a set of "improvements" Wednesday in the "accessibility and affordability" of the medication.
But Turing Pharmaceuticals did not say if it was actually reducing the $750 per-pill retail price of the drug Daraprim, as its CEO previously promised.
When asked for specifics, a Turing spokesman did not detail the extent to which the list of announced improvements were different than programs already in place to reduce the cost of the 62-year-old Daraprim for patients.
Nor did he detail how the supposed improvements would affect Turing's bottom line for Daraprim, leaving it unclear how much the measures would actually reduce company profits, if at all.